Page last updated: 2024-10-19

niacinamide and Recrudescence

niacinamide has been researched along with Recrudescence in 66 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

ExcerptRelevanceReference
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."9.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
"Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12."9.15Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)
"We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib."8.90[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014)
"The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)."8.89Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013)
"Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence."7.83Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016)
"Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)."7.81[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015)
"We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy."7.79[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013)
"There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)."7.78Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012)
"The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)."7.77[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011)
"Our study demonstrates the safety and potential benefit of sorafenib in reducing the incidence of hepatocellular carcinoma recurrence and in extending disease-free and overall survival for high-risk liver transplant recipients."7.76Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010)
"To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid."7.70Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000)
"A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day."7.66Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."6.78Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
"Adult glioblastoma patients at any recurrence after standard temozolomide chemoradiotherapy received sorafenib (400 mg twice daily) and continuous daily temozolomide (50 mg/m²/day)."6.76Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"Metastatic neuroblastoma is an aggressive malignancy with a poor prognosis."5.43Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. ( Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K, 2016)
"Sorafenib treatment was initiated."5.42[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015)
"The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al."5.38Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012)
" Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%."5.38High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012)
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."5.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
"Twelve patients with acute leukemia (11 with acute myeloid leukemia [AML]) received sorafenib on days 1 to 7 and then concurrently with cytarabine (1 g/m(2)) and clofarabine (stratum one: 40 mg/m(2), n = 10; stratum two [recent transplantation or fungal infection]: 20 mg/m(2), n = 2) on days 8 to 12."5.15Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. ( Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA, 2011)
"We report the long-term survival of a patient with metastatic hepatocellular carcinoma (HCC), successfully treated with transcatheter arterial chemoembolization (TACE)/hepatic arterial infusion chemotherapy (HAIC) combined with long-term administration of sorafenib."4.90[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy]. ( Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y, 2014)
"The aim of this study was to assess the safety and efficacy of sorafenib, with or without everolimus, in the treatment of recurrent hepatocellular carcinoma (HCC) after an orthotopic liver transplantation (OLT)."4.89Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. ( Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C, 2013)
"Liver resection combined with postoperative sorafenib to prevent recurrence remains a controversial approach for cases of hepatocellular carcinoma (HCC), especially cases with a high risk of recurrence."3.83Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. ( Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J, 2016)
"Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced hepatocellular carcinoma (HCC)."3.81[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection]. ( Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H, 2015)
"We report a case of multiple intrahepatic recurrence of hepatocellular carcinoma( HCC) that was successfully treated with transcatheter arterial chemoembolization( TACE) and sorafenib therapy."3.79[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy]. ( Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H, 2013)
" NanoHHI potently suppressed in vivo tumor growth of HCC xenografts in both subcutaneous and orthotopic milieus, and in contrast to sorafenib, resulted in significant attenuation of systemic metastases in the orthotopic setting."3.78Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma. ( Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF, 2012)
"There are scarce data on the use of sorafenib for the treatment of recurrent hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT)."3.78Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation? ( Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G, 2012)
"The role of sorafenib is unclear in multimodal treatment for hepatocellular carcinoma (HCC)."3.77[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma]. ( Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H, 2011)
"Our study demonstrates the safety and potential benefit of sorafenib in reducing the incidence of hepatocellular carcinoma recurrence and in extending disease-free and overall survival for high-risk liver transplant recipients."3.76Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. ( Busuttil, RW; Finn, RS; McTigue, M; Saab, S, 2010)
"To study the efficacy of tetracycline (or doxycycline) and nicotinamide in the treatment of less extensive bullous pemphigoid."3.70Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. ( Goon, AT; Khoo, LS; Tan, SH; Tan, T, 2000)
"A 60-year-old woman with recurrent papular and vesiculobullous lesions of erythema elevatum diutinum responded to treatment with 100 mg of oral niacinamide three times a day and 250 mg of tetracycline hydrochloride four times a day."3.66Erythema elevatum diutinum treated with niacinamide and tetracycline. ( Kohler, IK; Lorincz, AL, 1980)
"Patients with acute myeloid leukemia (AML) carrying FLT3-ITD mutations (FLT3-ITD+) who relapse after allogeneic transplantation (allo-SCT) have a very dismal prognosis with the currently available treatment options."2.84Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. ( Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T, 2017)
"Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24."2.78Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013)
"Sorafenib dose was escalated from 90 to 110 mg/m(2) twice daily with fixed doses of bevacizumab at 5 mg/kg every 3 weeks and cyclophosphamide at 50 mg/m(2) daily."2.78Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. ( Baker, SD; Billups, CA; Davidoff, AM; Fofana, D; Furman, WL; Hu, S; Leung, W; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Reddick, WE; Santana, VM; Spunt, SL; Stewart, CF; Turner, D; Wu, J, 2013)
"Adult glioblastoma patients at any recurrence after standard temozolomide chemoradiotherapy received sorafenib (400 mg twice daily) and continuous daily temozolomide (50 mg/m²/day)."2.76Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011)
"Pemphigus is a rare autoimmune bullous disorder."2.47[Pemphigus: a review]. ( Joly, P; Sin, C, 2011)
"Hepatocellular carcinoma is dramatically increasing in incidence that is mostly attributed to chronic hepatitis C and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and its clinical phenotype diabetes and obesity."2.46Review article: the management of hepatocellular carcinoma. ( Cabrera, R; Nelson, DR, 2010)
"In a retrospective analysis, 21 acute myeloid leukemia patients receiving single-agent sorafenib maintenance therapy in complete remission (CR) after hematopoietic stem cell transplantation (HSCT) were compared with a control group of 22 patients without maintenance."1.72Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. ( Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F, 2022)
"We studied three FLT3 ITD acute myeloid leukemia (AML) patients who relapsed after allogeneic haematopoietic stem cell transplantation (alloHSCT) and received multikinase inhibitor (MKI) sorafenib as part of salvage therapy."1.48The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. ( Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A, 2018)
"To explore the efficacy of sorafenib combined with chemotherapy and donor lymphocyte infusion (DLI) in patients with FLT3-positive acute myeloid leukemia (AML) relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT)."1.48[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation]. ( Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X, 2018)
"Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT."1.46Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. ( Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E, 2017)
"Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency."1.43[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia]. ( DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY, 2016)
"Metastatic neuroblastoma is an aggressive malignancy with a poor prognosis."1.43Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases. ( Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K, 2016)
"Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission, and sorafenib monotherapy as mauntenance treatment after complete remission (CR)."1.43[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation]. ( Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y, 2016)
"Sorafenib treatment was initiated."1.42[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib]. ( Chubachi, S; Nakagawa, T, 2015)
"The prognosis for children with acute myelogenous leukemia (AML) has improved with overall survival rates of up to 65% [Pui et al."1.38Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia. ( Cooper, T; Watt, TC, 2012)
" Grade 3-4 adverse events were observed in 92% of all patients necessitating sorafenib discontinuation in 77%."1.38High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. ( Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E, 2012)
"Thymoma and thymic carcinoma are rare neoplasms of the mediastinum, arising from the epithelial cells of the thymus."1.38Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. ( Luyken, J; Neuhaus, T, 2012)
"Patients with acute myeloid leukemia (AML) and internal tandem duplication of FMS-like tyrosine kinase receptor-3 gene (FLT3-ITD) mutation have poor prognoses and are often treated with allogeneic hematopoietic stem cell transplantation (HSCT)."1.37Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. ( Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M, 2011)
"Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway."1.37Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia. ( Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F, 2011)
"We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen."1.36A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. ( Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M, 2010)

Research

Studies (66)

TimeframeStudies, this research(%)All Research%
pre-19903 (4.55)18.7374
1990's2 (3.03)18.2507
2000's4 (6.06)29.6817
2010's53 (80.30)24.3611
2020's4 (6.06)2.80

Authors

AuthorsStudies
Aydin, S1
Passera, R1
Scaldaferri, M1
Dellacasa, CM1
Poggiu, M1
Cattel, F1
Zallio, F1
Brunello, L1
Giaccone, L1
Dogliotti, I1
Busca, A1
Witkowska-Patena, E1
Giżewska, A1
Dziuk, M1
Miśko, J1
Budzyńska, A1
Walęcka-Mazur, A1
Witt, EA1
Reissner, KJ1
Goto, H1
Kitagawa, N1
Sekiguchi, H1
Miyagi, Y1
Keino, D1
Sugiyama, M1
Sarashina, T1
Miyagawa, N1
Yokosuka, T1
Hamanoue, S1
Iwasaki, F1
Shiomi, M1
Goto, S1
Tanaka, Y1
Metzelder, SK1
Schroeder, T2
Lübbert, M1
Ditschkowski, M1
Götze, K1
Scholl, S1
Meyer, RG1
Dreger, P1
Basara, N1
Fey, MF1
Salih, HR1
Finck, A1
Pabst, T1
Giagounidis, A2
Kobbe, G2
Wollmer, E1
Finke, J1
Neubauer, A2
Burchert, A2
Lange, A1
Jaskula, E1
Lange, J1
Dworacki, G1
Nowak, D1
Simiczyjew, A1
Mordak-Domagala, M1
Sedzimirska, M1
Xuan, L2
Fan, ZP1
Zhang, Y2
Xu, N2
Ye, JY1
Zhou, X1
Wang, ZX1
Sun, J2
Liu, QF1
Huang, F2
Marafi, F1
Sasikumar, A1
Fathallah, W1
Esmail, A1
Xicoy, B1
Zamora, L1
Yordanova, A1
Hose, D1
Neben, K1
Witzens-Harig, M1
Gütgemann, I1
Raab, MS1
Moehler, T1
Goldschmidt, H1
Schmidt-Wolf, IG1
Zustovich, F1
Landi, L1
Lombardi, G2
Porta, C1
Galli, L1
Fontana, A1
Amoroso, D1
Galli, C1
Andreuccetti, M1
Falcone, A1
Zagonel, V1
Legault, G1
Kieran, MW1
Scott, RM1
Chordas, C1
Milla, SS1
Karajannis, MA1
Komatsu, H1
Tsukamoto, T1
Kodai, S1
Kanazawa, A1
Shimizu, S1
Yamazoe, S1
Ohira, G1
Nakajima, T1
Nakai, T1
Kawasaki, Y1
Kioka, K1
Mukai, R1
Wada, H1
Tomimaru, Y1
Hama, N1
Kawamoto, K1
Kobayashi, S1
Eguchi, H1
Umeshita, K1
Doki, Y1
Mori, M1
Nagano, H1
Perova, T1
Grandal, I1
Nutter, LM1
Papp, E1
Matei, IR1
Beyene, J1
Kowalski, PE1
Hitzler, JK1
Minden, MD1
Guidos, CJ1
Danska, JS1
Liegel, J1
Courville, E1
Sachs, Z1
Ustun, C1
Guidetti, A1
Carlo-Stella, C1
Locatelli, SL1
Malorni, W1
Mortarini, R1
Viviani, S1
Russo, D1
Marchianò, A1
Sorasio, R1
Dodero, A1
Farina, L1
Giordano, L1
Di Nicola, M1
Anichini, A1
Corradini, P1
Gianni, AM1
Bruedigam, C1
Bagger, FO1
Heidel, FH1
Paine Kuhn, C1
Guignes, S1
Song, A1
Austin, R1
Vu, T1
Lee, E1
Riyat, S1
Moore, AS1
Lock, RB1
Bullinger, L1
Hill, GR1
Armstrong, SA1
Williams, DA1
Lane, SW1
Lara, PN1
Moon, J1
Redman, MW1
Semrad, TJ1
Kelly, K1
Allen, JW1
Gitlitz, BJ1
Mack, PC1
Gandara, DR1
Gilbert, J1
Schell, MJ1
Zhao, X1
Murphy, B1
Tanvetyanon, T1
Leon, ME1
Neil Hayes, D1
Haigentz, M1
Saba, N1
Nieva, J1
Bishop, J1
Sidransky, D1
Ravi, R1
Bedi, A1
Chung, CH1
Watanabe, Y1
Nakaba, H1
Taniguchi, E1
Kikkawa, H1
Tamagawa, H1
Sasaki, M1
Kitayama, T1
Doi, Y1
Oguchi, Y1
Giri, S1
Hamdeh, S1
Bhatt, VR1
Schwarz, JK1
Badar, T1
Kantarjian, HM1
Nogueras-Gonzalez, GM1
Borthakur, G1
Garcia Manero, G1
Andreeff, M2
Konopleva, M2
Kadia, TM1
Daver, N1
Wierda, WG1
Luthra, R1
Patel, K1
Oran, B1
Champlin, R1
Ravandi, F3
Cortes, JE1
Nakagawa, T1
Chubachi, S1
Gon, H1
Kido, M1
Fukumoto, T1
Takebe, A1
Tanaka, M1
Kuramitsu, K1
Kinoshita, H1
Fukushima, K1
Urade, T1
So, S1
Shinzeki, M1
Matsumoto, I1
Ajiki, T1
Ku, Y1
Röllig, C1
Serve, H1
Hüttmann, A1
Noppeney, R1
Müller-Tidow, C1
Krug, U1
Baldus, CD1
Brandts, CH1
Kunzmann, V1
Einsele, H1
Krämer, A1
Schäfer-Eckart, K1
Krause, SW1
Mackensen, A2
Aulitzky, W1
Herbst, R1
Hänel, M1
Kiani, A1
Frickhofen, N1
Kullmer, J1
Kaiser, U1
Link, H1
Geer, T1
Reichle, A1
Junghanß, C1
Repp, R1
Heits, F1
Dürk, H1
Hase, J1
Klut, IM1
Illmer, T1
Bornhäuser, M1
Schaich, M1
Parmentier, S1
Görner, M1
Thiede, C1
von Bonin, M1
Schetelig, J1
Kramer, M1
Berdel, WE1
Ehninger, G1
Yokoo, H1
Kamiyama, T1
Kakisaka, T1
Orimo, T1
Wakayama, K1
Shimada, S1
Tsuruga, Y1
Kamachi, H1
Taketomi, A1
Matoba, H1
Seta, S1
Lei, J1
Zhong, J1
Hao, J1
Liu, Z1
Zhang, P1
Wu, L1
Yan, L1
Zhu, J1
Zeng, Y1
Li, B1
Wen, T1
Wang, W1
Fan, Z1
Jiang, Q1
Gao, Y1
Liu, Q1
Liu, XS1
Long, H1
Huang, YX1
Xu, JH1
Zhu, JY1
DU, QF1
Wu, BY1
Okada, K1
Nakano, Y1
Yamasaki, K1
Nitani, C1
Fujisaki, H1
Hara, J1
Zu, YL1
Zhang, YL1
Zhou, J1
Han, LJ1
Zhao, HF1
Gui, RR1
Hou, YJ1
Song, YP1
Rautenberg, C1
Nachtkamp, K1
Dienst, A1
Schmidt, PV1
Heyn, C1
Kondakci, M1
Germing, U1
Haas, R1
Sid, S1
Rey, J1
Charbonnier, A1
D'Incan, E1
Mohty, B1
Blaise, D1
Vey, N1
Domont, J1
Massard, C1
Lassau, N1
Armand, JP1
Le Cesne, A1
Soria, JC1
Cabrera, R1
Nelson, DR1
Fesler, MJ1
Richart, JM1
Petruska, PJ1
Reardon, DA1
Vredenburgh, JJ1
Desjardins, A1
Peters, K1
Gururangan, S1
Sampson, JH1
Marcello, J1
Herndon, JE1
McLendon, RE1
Janney, D1
Friedman, AH1
Bigner, DD1
Friedman, HS1
Pratz, KW1
Cho, E1
Levis, MJ1
Karp, JE1
Gore, SD1
McDevitt, M1
Stine, A1
Zhao, M1
Baker, SD3
Carducci, MA1
Wright, JJ1
Rudek, MA1
Smith, BD1
Winkler, J1
Rech, D1
Kallert, S1
Rech, J1
Meidenbauer, N1
Roesler, W1
Saab, S1
McTigue, M1
Finn, RS1
Busuttil, RW1
Bernard, P1
Charneux, J1
Joly, P1
Sin, C1
Sharma, M1
Bayraktar, UD1
Chiattone, A1
Bashir, Q1
Giralt, S1
Chen, J1
Qazilbash, M1
Kebriaei, P1
Cortes, J2
McCue, D1
Kantarjian, H2
Champlin, RE1
de Lima, M1
Inaba, H1
Rubnitz, JE1
Coustan-Smith, E1
Li, L1
Furmanski, BD1
Mascara, GP1
Heym, KM1
Christensen, R1
Onciu, M1
Shurtleff, SA1
Pounds, SB1
Pui, CH1
Ribeiro, RC1
Campana, D1
Al-Kali, A1
Faderl, S1
Jones, D1
Abril, C1
Pierce, S1
Brandt, M1
Xu, Y1
Chenna, V1
Hu, C1
Sun, HX1
Khan, M1
Bai, H1
Yang, XR1
Zhu, QF1
Sun, YF1
Maitra, A1
Fan, J1
Anders, RA1
Takahara, T1
Nitta, H1
Hasegawa, Y1
Itou, N1
Takahashi, M1
Wakabayashi, G1
Watt, TC1
Cooper, T1
Ishiko, T1
Beppu, T1
Chikamoto, A1
Tanaka, H1
Masuda, T1
Okabe, H1
Mima, K1
Horino, K1
Takamori, H1
Nakahara, O1
Baba, H1
Staufer, K1
Fischer, L1
Seegers, B1
Vettorazzi, E1
Nashan, B1
Sterneck, M1
Nadarajah, JT1
Collins, M1
Raboud, J1
Su, D1
Rao, K1
Loutfy, MR1
Walmsley, S1
Vitale, A1
Boccagni, P1
Kertusha, X1
Zanus, G1
D'Amico, F1
Lodo, E1
Pastorelli, D1
Ramirez Morales, R1
Senzolo, M1
Burra, P1
Cillo, U1
Zavaglia, C1
Airoldi, A1
Mancuso, A1
Vangeli, M1
Viganò, R1
Cordone, G1
Gentiluomo, M1
Belli, LS1
Neuhaus, T1
Luyken, J1
Navid, F1
McCarville, MB1
Stewart, CF1
Billups, CA1
Wu, J1
Davidoff, AM1
Spunt, SL1
Furman, WL1
McGregor, LM1
Hu, S1
Panetta, JC1
Turner, D1
Fofana, D1
Reddick, WE1
Leung, W1
Santana, VM1
Suarez-Pinzon, WL1
Mabley, JG1
Power, R1
Szabó, C1
Rabinovitch, A1
Diago, T1
Pulido, JS1
Molina, JR1
Collett, LC1
Link, TP1
Ryan, EH1
Kohler, IK1
Lorincz, AL1
Kitakaze, M1
Minamino, T1
Node, K1
Komamura, K1
Shinozaki, Y1
Chujo, M1
Mori, H1
Inoue, M1
Hori, M1
Kamada, T1
Hornschuh, B1
Hamm, H1
Wever, S1
Hashimoto, T1
Schröder, U1
Bröcker, EB1
Zillikens, D1
Goon, AT1
Tan, SH1
Khoo, LS1
Tan, T1
Loo, WJ1
Dean, D1
Wojnarowska, F1
Pieper, GM1
Gross, GJ1
Prasad, RS1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857]Phase 212 participants (Actual)Interventional2011-04-30Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA)
A Phase II Trial of PS-341 (NSC-681239) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00068289]Phase 20 participants Interventional2003-09-30Completed
A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer[NCT00182689]Phase 289 participants (Actual)Interventional2005-07-31Completed
A Randomized Phase II Trial of Weekly Topotecan With and Without AVE0005 (Aflibercept; NSC-724770) in Patients With Platinum Treated Extensive Stage Small Cell Lung Cancer (E-SCLC)[NCT00828139]Phase 2189 participants (Actual)Interventional2009-05-31Completed
A Double-blind, Placebo-controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed AML ≤60 Years of Age[NCT00893373]Phase 2276 participants (Actual)Interventional2009-03-31Completed
Prospective Evaluation of Sorafenib Combined With Standard Therapy in Newly Diagnosed Adult Core-binding Factor Acute Myeloid Leukemia: an Open-label , Randomised Controlled, Multicenter Phase II Trial[NCT05404516]Phase 288 participants (Anticipated)Interventional2020-01-01Recruiting
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients[NCT03023124]Phase 250 participants (Anticipated)Interventional2018-03-04Recruiting
A Prospective Cohort Study of Single Agent Memantine in Patients With Child-Pugh Score ≥ B7 Cirrhosis and Hepatocellular Carcinoma[NCT06007846]Phase 2/Phase 312 participants (Anticipated)Interventional2023-07-31Recruiting
Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493]Phase 232 participants (Actual)Interventional2007-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Objective Response Rates

Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Response Rate to Sorafenib

To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Objective Response (Confirmed and Unconfirmed, Complete and Partial Responses Per RECIST)

Complete Response (CR) is a complete disappearance of all measurable and non-measurable disease. No new lesions, no disease related symptoms. Normalization of markers and other abnormal lab values. Partial Response (PR) is greater than or equal to 30% decrease under baseline of the sum of longest diameters of all target measurable lesions. No unequivocal progression of non-measurable disease. No new lesions. Confirmation of CR or PR means a repeat scan at least 4 weeks apart documented before progression or symptomatic deterioration. (NCT00182689)
Timeframe: 8 weeks to 2 years

Interventionpercentage of participants (Number)
Platinum-Sensitive11
Platinum-Refractory2

Overall Survival

Measured from time of registration to death, or last contact date (NCT00182689)
Timeframe: 0 - 2 years

Interventionmonths (Median)
Platinum-Sensitive6.7
Platinum-Refractory5.3

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Adverse Events (AEs) are reported by the CTCAE (NCI Common Terminology Criteria for Adverse Events) Version 3.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal. (NCT00182689)
Timeframe: Patients were assessed for adverse events after completion of every 28-day cycle.

,
InterventionParticipants with a given type of AE (Number)
AST, SGOTAllergic reaction/hypersensitivityAnorexiaAtaxia (incoordination)Bilirubin (hyperbilirubinemia)ConfusionDehydrationDiarrheaDizzinessDyspnea (shortness of breath)Fatigue (asthenia, lethargy, malaise)Fever in absence of neutropenia, ANC lt1.0x10e9/LHemoglobinHypertensionINR (of prothrombin time)Inf w/normal ANC or Gr 1-2 neutrophils - SkinInf w/normal ANC or Gr 1-2 neutrophils - UTILipaseMuscle weakness, not d/t neuropathy - body/generalNauseaNeuropathy: sensoryPTT (Partial thromboplastin time)Pain - Abdomen NOSPain - Extremity-limbPain - JointPain-Other (Specify)PancreatitisPhosphate, serum-low (hypophosphatemia)Pleural effusion (non-malignant)Pneumonitis/pulmonary infiltratesPotassium, serum-low (hypokalemia)Rash/desquamationRash: acne/acneiformRash: erythema multiformeRash: hand-foot skin reactionSodium, serum-low (hyponatremia)Speech impairment (e.g., dysphasia or aphasia)Syncope (fainting)VomitingWeight loss
Platinum Refractory0111122200311000111101211111100201821011
Platinum Sensitive1020010013500311000110101101011120910100

Overall Survival

Estimated to within at least 15% (95% confidence interval). (NCT00828139)
Timeframe: Weekly, up to 2 years.

Interventionmonths (Median)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept6.0
Platinum Sensitivity Treated With Topotecan Alone4.6
Platinum Refractory Treated With Topotecan + Ziv-aflibercept4.6
Platinum Refractory Treated With Topotecan Aloine4.2

Progression-free Survival (PFS)

"From the date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause.~Progression is defined as 20% increase in the sum of longest diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site. Death due to disease without prior documentation of progression and without symptomatic deterioration." (NCT00828139)
Timeframe: Disease assessments were performed every 6 weeks, up to 2 years.

InterventionMonths (Median)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept1.8
Platinum Sensitivity Treated With Topotecan Alone1.3
Platinum Refractory Treated With Topotecan + Ziv-aflibercept1.4
Platinum Refractory Treated With Topotecan Aloine1.4

Response Rate (Confirmed and Unconfirmed, Complete and Partial Responses)

"The number of confirmed and unconfirmed complete and partial responses in the subset of patients with measurable disease per RECIST 1.0. Estimated to within at least 17% (95% confidence interval).~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by magnetic resonance imaging (MRI): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR." (NCT00828139)
Timeframe: Disease assessment for response were performed every 6 weeks, up to 2 years.

Interventionproportion of participants (Number)
Platinum-Sensitive Treated With Topotecan and Ziv-aflibercept0.02
Platinum Sensitivity Treated With Topotecan Alone0
Platinum Refractory Treated With Topotecan + Ziv-aflibercept0.02
Platinum Refractory Treated With Topotecan Aloine0

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs

Adverse Events (AEs) are reported by CTCAE Version 3.0. Only adverse events that are possibly, probably or definitely related to study drug are reported. The events listed here are not necessary to be included in Serious Adverse Event. A serious event could be death, life-threatening, hospitalization, disability or permanent damage, congenital anomaly...Grade 3 through 5 adverse event may not meet the criterion of serious adverse event. (NCT00828139)
Timeframe: Toxicity assessment was evaluated after each cycle (21 days), up to 2 years.

,
InterventionParticipants (Number)
AST, SGOTAnorexiaBilirubin (hyperbilirubinemia)Bronchospasm, wheezingCalcium, serum-high (hypercalcemia)Cardiac-ischemia/infarctionColitis, infectious (e.g., Clostridium difficile)ConfusionConstipationCreatinineDehydrationDiarrheaDizzinessDyspnea (shortness of breath)Fatigue (asthenia, lethargy, malaise)Febrile neutropeniaGGT (gamma-glutamyl transpeptidase)HemoglobinHemolysisHemorrhage, GI - Upper GI NOSHemorrhage, pulmo/upper resp- Bronchopulmonary NOSHemorrhage, pulmonary/upper respiratory - LungHemorrhage, pulmonary/upper respiratory - NoseHypertensionINR (of prothrombin time)Inf (clin/microbio) w/Gr 3-4 neuts - ColonInf (clin/microbio) w/Gr 3-4 neuts - LungInf w/normal ANC or Gr 1-2 neutrophils - BronchusInf w/normal ANC or Gr 1-2 neutrophils - LungInf w/normal ANC or Gr 1-2 neutrophils - UTIInfection with unknown ANC - BloodInfection with unknown ANC - Lung (pneumonia)Left ventricular systolic dysfunctionLeukocytes (total WBC)Leukoencephalopathy (radiolographic findings)LipaseLymphopeniaMucositis/stomatitis (clinical exam) - Oral cavityMuscle weakness, not d/t neuropathy - body/generalNauseaNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - Chest wallPain - Head/headachePain - Pain NOSPlateletsPneumonitis/pulmonary infiltratesPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)ProteinuriaPsychosis (hallucinations/delusions)Renal failureSeizureSodium, serum-high (hypernatremia)Sodium, serum-low (hyponatremia)Syndromes-Other (Specify)Thrombosis/thrombus/embolismVoice changes/dysarthriaVomitingWeight loss
Topotecan2201000011101130071000000010012002200130112300001711101201100000
Ziv-aflibercept + Topotecan1310111300612715119121123110110011171151343031212900310010612121

6 Month Progression Free Survival (PFS)

Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Sorafenib + Temozolomide9.4

Pharmacokinetics: AUC-24

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionug*H/L (Geometric Mean)
EIAEDs-Day 145309.7
EIAEDs-Day 2847148.2
Non-EIAEDs-Day 145238.7
Non-EIAEDs-Day 28128820.8

Pharmacokinetics: C-max

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionug/L (Geometric Mean)
EIAEDs-Day 13397.3
EIAEDs-Day 283813.9
Non-EIAEDs-Day 13155.1
Non-EIAEDs-Day 288118.8

Pharmacokinetics: T-max

Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months

Interventionhours (Median)
EIAEDs-Day 18.2
EIAEDs-Day 282.1
Non-EIAEDs-Day 124.0
Non-EIAEDs-Day 284.2

Safety and Toxicity of Combination

Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months

Interventionparticipants (Number)
Sorafenib + Temozolomide19

Reviews

5 reviews available for niacinamide and Recrudescence

ArticleYear
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The

2014
Review article: the management of hepatocellular carcinoma.
    Alimentary pharmacology & therapeutics, 2010, Feb-15, Volume: 31, Issue:4

    Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black Pe

2010
[Bullous pemphigoid: a review].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:3

    Topics: Aged; Azathioprine; Clobetasol; Combined Modality Therapy; Dapsone; Dose-Response Relationship, Drug

2011
[Pemphigus: a review].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:3

    Topics: Adrenal Cortex Hormones; Combined Modality Therapy; Drug Therapy, Combination; Epidermal Growth Fact

2011
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
    European journal of gastroenterology & hepatology, 2013, Volume: 25, Issue:2

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

2013

Trials

12 trials available for niacinamide and Recrudescence

ArticleYear
Head-to-Head Comparison of 18F-Prostate-Specific Membrane Antigen-1007 and 18F-Fluorocholine PET/CT in Biochemically Relapsed Prostate Cancer.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:12

    Topics: Aged; Aged, 80 and over; Choline; Humans; Male; Middle Aged; Niacinamide; Oligopeptides; Positron Em

2019
Sorafenib in patients with refractory or recurrent multiple myeloma.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
    Anticancer research, 2013, Volume: 33, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

2013
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8

    Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide;

2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-15, Volume: 20, Issue:22

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular S

2014
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte

2015
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral oncology, 2015, Volume: 51, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neopl

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:16

    Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Com

2015
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
    European journal of haematology, 2017, Volume: 98, Issue:4

    Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoi

2017
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
    Journal of neuro-oncology, 2011, Volume: 101, Issue:1

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra

2011
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Aug-20, Volume: 29, Issue:24

    Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides;

2011
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1

    Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols

2013

Other Studies

49 other studies available for niacinamide and Recrudescence

ArticleYear
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    International journal of hematology, 2022, Volume: 116, Issue:6

    Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acut

2022
The effects of nicotinamide on reinstatement to cocaine seeking in male and female Sprague Dawley rats.
    Psychopharmacology, 2020, Volume: 237, Issue:3

    Topics: Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Cues; Dopamine Uptake Inhibitors;

2020
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
    Journal of pediatric hematology/oncology, 2017, Volume: 39, Issue:5

    Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Scree

2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 86

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free

2017
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
    PloS one, 2018, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantat

2018
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
    Zhonghua nei ke za zhi, 2018, May-01, Volume: 57, Issue:5

    Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3;

2018
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:1

    Topics: Brain; Brain Neoplasms; Fluorine Radioisotopes; Glioblastoma; Humans; Magnetic Resonance Imaging; Ma

2020
Current treatment of myeloproliferative neoplasias: three scenarios.
    Medicina clinica, 2020, 02-28, Volume: 154, Issue:4

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous,

2020
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; F

2013
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, The

2013
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
    Science translational medicine, 2014, May-14, Volume: 6, Issue:236

    Topics: Administration, Oral; Adult; Aminopyridines; Animals; Cell Proliferation; Cell Survival; Child; Fema

2014
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
    Haematologica, 2014, Volume: 99, Issue:11

    Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoie

2014
Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.
    Cell stem cell, 2014, Dec-04, Volume: 15, Issue:6

    Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cells, Cultured; Disease Models, Animal; Gene Expression

2014
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinas

2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
    American journal of hematology, 2015, Volume: 90, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms

2015
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9

    Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans

2015
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:9

    Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hum

2015
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectom

2015
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male;

2015
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Oncotarget, 2016, Jul-05, Volume: 7, Issue:27

    Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival;

2016
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2016, Volume: 37, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem

2016
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
    Zhongguo shi yan xue ye xue za zhi, 2016, Volume: 24, Issue:2

    Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Co

2016
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
    Cancer medicine, 2016, Volume: 5, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Drug Resist

2016
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
    Zhonghua nei ke za zhi, 2016, Aug-01, Volume: 55, Issue:8

    Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine K

2016
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
    Clinical lymphoma, myeloma & leukemia, 2017, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoiet

2017
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
    Investigational new drugs, 2010, Volume: 28, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans;

2010
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
    Leukemia research, 2010, Volume: 34, Issue:10

    Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia

2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
    Leukemia, 2010, Volume: 24, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regul

2010
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
    Leukemia research, 2010, Volume: 34, Issue:10

    Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host D

2010
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2010, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease

2010
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011, Volume: 17, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonate

2011
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
    Clinical lymphoma, myeloma & leukemia, 2011, Volume: 11, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female;

2011
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5

    Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line

2012
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
    Transplantation proceedings, 2011, Volume: 43, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans;

2011
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
    Pediatric blood & cancer, 2012, Volume: 59, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acut

2012
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy

2011
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Transplant international : official journal of the European Society for Organ Transplantation, 2012, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carci

2012
Infectious complications of Bio-Alcamid filler used for HIV-related facial lipoatrophy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:11

    Topics: Acrylic Resins; Anti-HIV Agents; Bacterial Infections; Face; Female; HIV-Associated Lipodystrophy Sy

2012
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
    Transplantation proceedings, 2012, Volume: 44, Issue:7

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver

2012
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
    Targeted oncology, 2012, Volume: 7, Issue:4

    Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged

2012
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
    Diabetes, 2003, Volume: 52, Issue:7

    Topics: Aging; Animals; Apoptosis; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Interferon-gamma; Interleuk

2003
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
    Mayo Clinic proceedings, 2008, Volume: 83, Issue:2

    Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Dru

2008
Erythema elevatum diutinum treated with niacinamide and tetracycline.
    Archives of dermatology, 1980, Volume: 116, Issue:6

    Topics: Drug Therapy, Combination; Erythema; Female; Humans; Middle Aged; Niacinamide; Recurrence; Tetracycl

1980
Role of activation of ectosolic 5'-nucleotidase in the cardioprotection mediated by opening of K+c channels.
    The American journal of physiology, 1996, Volume: 270, Issue:5 Pt 2

    Topics: 5'-Nucleotidase; Adenosine Triphosphate; Animals; Benzopyrans; Cromakalim; Dogs; Enzyme Activation;

1996
Treatment of 16 patients with bullous pemphigoid with oral tetracycline and niacinamide and topical clobetasol.
    Journal of the American Academy of Dermatology, 1997, Volume: 36, Issue:1

    Topics: Administration, Cutaneous; Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents; Cl

1997
Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore.
    Singapore medical journal, 2000, Volume: 41, Issue:7

    Topics: Aged; Anti-Bacterial Agents; Complement C3; Diarrhea; Doxycycline; Drug Combinations; Female; Fluore

2000
A severe persistent case of recurrent pemphigoid gestationis successfully treated with minocycline and nicotinamide.
    Clinical and experimental dermatology, 2001, Volume: 26, Issue:8

    Topics: Adult; Anti-Bacterial Agents; Female; Humans; Immunosuppressive Agents; Minocycline; Niacinamide; Pe

2001
Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.
    Circulation, 1987, Volume: 76, Issue:4

    Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Dogs;

1987
Recurrent aphthous ulcers.
    The Medical journal of Australia, 1972, Feb-12, Volume: 1, Issue:7

    Topics: Chronic Disease; Humans; Niacinamide; Recurrence; Stomatitis, Aphthous

1972